A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19.
一项随机、双盲、安慰剂对照试验，研究尼克酰胺纳米混合物治疗轻度至中度 COVID-19 患者的疗效
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-62423-4
Kim Jung Ho, Kym Sungmin, Kim Shin-Woo, Park Dae Won, Kwon Ki Tae, Seo Jun-Won, Yu Seungjin, Choi Goeun, N Sanoj Rejinold, Choy Jin-Ho, Jin Geun-Woo, Choi Jun Yong
